Trials / Recruiting
RecruitingNCT06067841
A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
A Phase 1, Open-label Study of BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 140 (estimated)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety, tolerability, and preliminary efficacy of BMS-986460 in men with Metastatic Castration-resistant Prostate Cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986460 | Specified dose on specified days. |
Timeline
- Start date
- 2023-10-18
- Primary completion
- 2029-08-24
- Completion
- 2031-07-27
- First posted
- 2023-10-05
- Last updated
- 2026-02-04
Locations
8 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06067841. Inclusion in this directory is not an endorsement.